{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:08:41Z","timestamp":1792372121365,"version":"4.4.0"},"reference-count":190,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009742","name":"Dr \u00c5ke Olssons Stiftelse f\u00f6r Haematologisk Forskning","doi-asserted-by":"publisher","award":["2025-00284"],"award-info":[{"award-number":["2025-00284"]}],"id":[{"id":"10.13039\/501100009742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["254135 PT IPT"],"award-info":[{"award-number":["254135 PT IPT"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS-1021310"],"award-info":[{"award-number":["SLS-1021310"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS-1023097"],"award-info":[{"award-number":["SLS-1023097"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006689","name":"Sardinian Association for Research on Gynaecological Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["31013"],"award-info":[{"award-number":["31013"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21267"],"award-info":[{"award-number":["21267"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-23IAHU-0002"],"award-info":[{"award-number":["ANR-23IAHU-0002"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.semcancer.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:13:42Z","timestamp":1770225222000},"page":"16-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Evolutionary trajectories of myelodysplastic syndromes\/neoplasms"],"prefix":"10.1016","volume":"120","author":[{"given":"Maria","family":"Creignou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Sarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2057-7187","authenticated-orcid":false,"given":"Elsa","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2026.01.006_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib2","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","article-title":"The genetic basis of myelodysplasia and its clinical relevance","volume":"122","author":"Cazzola","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib4","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib5","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib6","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib7","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.2021011323","article-title":"Relationship between clone metrics and clinical outcome in clonal cytopenia","volume":"138","author":"Gall\u00ec","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib9","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib10","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1182\/blood.2021010815","article-title":"Incidence and prognosis of clonal hematopoiesis in patients with chronic idiopathic neutropenia","volume":"138","author":"Tsaknakis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib12","first-page":"1161","article-title":"Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals","volume":"135","author":"van Zeventer","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ccell.2023.04.006","article-title":"Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population","volume":"41","author":"van Zeventer","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib15","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib16","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib17","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib18","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2024025771","article-title":"How I manage patients with unexplained cytopenia","volume":"145","author":"Malcovati","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib19","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1158\/1078-0432.CCR-24-3683","article-title":"Clonal evolution of PPM1D mutations in the spectrum of myeloid disorders","volume":"31","author":"Fandrei","year":"2025","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.semcancer.2026.01.006_bib20","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib22","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.semcancer.2026.01.006_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2026.01.006_bib24","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib25","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1182\/blood.2023023723","article-title":"Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes","volume":"144","author":"Sirenko","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib27","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.1038\/ncomms10615","article-title":"Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage","volume":"7","author":"Alsafadi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.01.006_bib28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib29","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1038\/s41467-018-06063-x","article-title":"Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia","volume":"9","author":"Shiozawa","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.01.006_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/wrna.1222","article-title":"Splicing factor mutations and cancer","volume":"5","author":"Yoshida","year":"2014","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"10.1016\/j.semcancer.2026.01.006_bib31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/leu.2016.251","article-title":"Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts","volume":"31","author":"Mupo","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2026.01.006_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","article-title":"DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development","volume":"99","author":"Okano","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib34","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in haematological malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2026.01.006_bib36","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12239","article-title":"TET proteins and 5-methylcytosine oxidation in hematological cancers","volume":"263","author":"Ko","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.semcancer.2026.01.006_bib38","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1101\/gad.260174.115","article-title":"Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis","volume":"29","author":"Rasmussen","year":"2015","journal-title":"Genes Dev."},{"key":"10.1016\/j.semcancer.2026.01.006_bib39","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-14-0739","article-title":"TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor-binding sites in chronic myelomonocytic leukemia","volume":"75","author":"Yamazaki","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2026.01.006_bib40","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3324\/haematol.2010.030015","article-title":"IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications","volume":"95","author":"Cazzola","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.01.006_bib41","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib42","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.stem.2025.04.012","article-title":"Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia","volume":"32","author":"Sirenko","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib45","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/leu.2016.2","article-title":"BCOR regulates myeloid cell proliferation and differentiation","volume":"30","author":"Cao","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib46","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/leu.2013.80","article-title":"Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies","volume":"27","author":"Khan","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2162-3619-3-13","article-title":"Cohesin mutations in myeloid malignancies: underlying mechanisms","volume":"3","author":"Leeke","year":"2014","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib48","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.stem.2015.09.017","article-title":"Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation","volume":"17","author":"Mazumdar","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib49","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2014-04-567057","article-title":"Genetic alterations of the cohesin complex genes in myeloid malignancies","volume":"124","author":"Thota","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib50","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib51","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib52","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib53","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/blood.2024023840","article-title":"Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion","volume":"144","author":"Montoro","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib54","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib55","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.01.006_bib56","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood.2025028619","article-title":"A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery","volume":"146","author":"Roncador","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib57","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1038\/s41375-023-02003-x","article-title":"Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets","volume":"37","author":"Mori","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib58","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","article-title":"New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge","volume":"30","author":"Schanz","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2018.07.003","article-title":"Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations","volume":"34","author":"Lee","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib60","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1038\/s41375-022-01727-6","article-title":"Srsf2P95H\/+ co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice","volume":"36","author":"Xu","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood.2023019964","article-title":"The lifelong natural history of clonal hematopoiesis and its links to myeloid neoplasia","volume":"143","author":"Fabre","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib62","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib64","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2352-3026(23)00340-X","article-title":"Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study","volume":"11","author":"Cargo","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib65","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1182\/blood-2015-08-663237","article-title":"Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression","volume":"126","author":"Cargo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib66","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib67","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41375-023-01861-9","article-title":"Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives","volume":"37","author":"Barosi","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib68","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2018-08-867333","article-title":"The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis","volume":"133","author":"Cargo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib69","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2024024187","article-title":"JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism","volume":"144","author":"Zon","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib70","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","article-title":"The longitudinal dynamics and natural history of clonal haematopoiesis","volume":"606","author":"Fabre","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib71","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41467-020-20565-7","article-title":"Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis","volume":"12","author":"Gao","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.01.006_bib72","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat. Genet"},{"key":"10.1016\/j.semcancer.2026.01.006_bib73","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/asheducation-2015.1.299","article-title":"The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)","volume":"2015","author":"Malcovati","year":"2015","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.semcancer.2026.01.006_bib74","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","article-title":"Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo","volume":"25","author":"Woll","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib75","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood-2017-03-776070","article-title":"SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells","volume":"130","author":"Mortera-Blanco","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.2020004850","article-title":"SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS","volume":"136","author":"Malcovati","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib77","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41588-023-01472-1","article-title":"Multiparameter prediction of myeloid neoplasia risk","volume":"55","author":"Gu","year":"2023","journal-title":"Nat. Genet"},{"key":"10.1016\/j.semcancer.2026.01.006_bib78","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2024024756","article-title":"Risk prediction for clonal cytopenia: multicenter real-world evidence","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib79","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid."},{"key":"10.1016\/j.semcancer.2026.01.006_bib80","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/251437a0","article-title":"Distinct haematological disorder with deletion of long arm of no. 5 chromosome","volume":"251","author":"Van den Berghe","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib81","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1182\/blood.V99.12.4638","article-title":"Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome","volume":"99","author":"Boultwood","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nm.2063","article-title":"A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome","volume":"16","author":"Barlow","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib83","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q- syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib84","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","article-title":"Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS","volume":"26","author":"Schneider","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib85","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib86","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","article-title":"Persistent malignant stem cells in del(5q) myelodysplasia in remission","volume":"363","author":"Tehranchi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib87","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib88","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2026.01.006_bib89","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/2159-8290.CD-18-1391","article-title":"A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1","volume":"9","author":"Loizou","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2026.01.006_bib90","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cell.2014.01.051","article-title":"Synonymous mutations frequently act as driver mutations in human cancers","volume":"156","author":"Supek","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib91","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood.2025029691","article-title":"A clinical guide to TP53 mutations in myeloid neoplasms","volume":"146","author":"Urrutia","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib92","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2026.01.006_bib93","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ajh.27655","article-title":"TP53 -mutated myeloid neoplasms: 2024 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shah","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib94","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","article-title":"Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"37","author":"Badar","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib95","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib96","article-title":"TP53 mutations in acute leukemias and myelodysplastic syndromes: insights and treatment updates","volume":"44","author":"Santini","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet."},{"key":"10.1016\/j.semcancer.2026.01.006_bib97","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib98","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","article-title":"Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations","volume":"132","author":"Pellagatti","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib99","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/blood-2017-05-783050","article-title":"Gene expression and risk of leukemic transformation in myelodysplasia","volume":"130","author":"Shiozawa","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib100","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1182\/bloodadvances.2024014965","article-title":"Distinct routes of clonal progression in SF3B1-mutant myelodysplastic syndromes","volume":"9","author":"Sarchi","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.01.006_bib101","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1182\/bloodadvances.2024014965","article-title":"Distinct routes of clonal progression in SF3B1-mutant myelodysplastic syndromes","volume":"9","author":"Sarchi","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.01.006_bib102","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","article-title":"Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis","volume":"97","author":"Broseus","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.01.006_bib103","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib104","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1038\/s41375-020-01106-z","article-title":"Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms","volume":"35","author":"Todisco","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib105","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib106","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/s41467-023-38515-4","article-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","volume":"14","author":"Kewan","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2026.01.006_bib107","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41591-018-0267-4","article-title":"Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level","volume":"25","author":"Chen","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib108","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2643-3230.BCD-21-0128","article-title":"Distinct patterns of clonal evolution drive myelodysplastic syndrome progression to secondary acute myeloid leukemia","volume":"3","author":"Guess","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.semcancer.2026.01.006_bib109","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/2643-3230.BCD-21-0155","article-title":"Convergent clonal evolution of signaling gene mutations is a hallmark of myelodysplastic syndrome progression","volume":"3","author":"Menssen","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.semcancer.2026.01.006_bib110","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib111","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature08851","article-title":"Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia","volume":"464","author":"Raaijmakers","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib112","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood-2014-05-574889","article-title":"Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome","volume":"124","author":"Kulasekararaj","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib113","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.22.00710","article-title":"Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria","volume":"41","author":"Gurnari","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib114","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib115","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood.2022015790","article-title":"Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages","volume":"140","author":"Feurstein","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib116","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1182\/bloodadvances.2023010045","article-title":"Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41","volume":"7","author":"Homan","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.01.006_bib117","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.2022019304","article-title":"Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity","volume":"142","author":"Molteni","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib118","first-page":"1615","article-title":"Clonal hematopoiesis in the inherited bone marrow failure syndromes","volume":"136","author":"Tsai","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib119","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41576-019-0139-x","article-title":"Somatic genetic rescue in Mendelian haematopoietic diseases","volume":"20","author":"Revy","year":"2019","journal-title":"Nat. Rev. Genet"},{"key":"10.1016\/j.semcancer.2026.01.006_bib120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood.2022017717","article-title":"Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management","volume":"145","author":"Sahoo","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib121","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germ line DDX41 mutations define a unique subtype of myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib122","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","article-title":"Inherited and somatic defects in DDX41 in myeloid neoplasms","volume":"27","author":"Polprasert","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2026.01.006_bib123","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa041331","article-title":"Mutation of CEBPA in familial acute myeloid leukemia","volume":"351","author":"Smith","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib124","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib125","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood.2019001807","article-title":"Concordance for clonal hematopoiesis is limited in elderly twins","volume":"135","author":"Fabre","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib126","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood.2019001793","article-title":"Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality","volume":"135","author":"Hansen","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib127","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib128","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41588-025-02250-x","article-title":"Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy","volume":"57","author":"Liu","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2026.01.006_bib129","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib130","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000632","article-title":"Molecular landscape of therapy-related myeloid neoplasms in patients previously treated for gynecologic and breast cancers","volume":"5","author":"Khalife-Hachem","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.semcancer.2026.01.006_bib131","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","article-title":"Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS","volume":"35","author":"Kuendgen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib132","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib133","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/leu.2015.258","article-title":"Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation","volume":"30","author":"Radivoyevitch","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib134","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2018.07.013","article-title":"Incidence and survival of therapy related myeloid neoplasm in United States","volume":"71","author":"Guru Murthy","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2026.01.006_bib135","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","article-title":"Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications","volume":"108","author":"Nilsson","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.01.006_bib136","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41375-023-01864-6","article-title":"Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective","volume":"37","author":"Moreno Berggren","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib137","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2026.01.006_bib138","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(15)00094-0","article-title":"Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study","volume":"2","author":"Leuraud","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib139","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1056\/NEJMoa2502098","article-title":"Medical imaging and pediatric and adolescent hematologic cancer risk","volume":"393","author":"Smith-Bindman","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib140","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3324\/haematol.2017.167478","article-title":"Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials","volume":"102","author":"Eichenauer","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.01.006_bib141","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2012.44.5791","article-title":"Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials","volume":"31","author":"Koontz","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib142","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-22-1622","article-title":"Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience","volume":"28","author":"Marmouset","year":"2022","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.semcancer.2026.01.006_bib143","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib144","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis","volume":"19","author":"Christiansen","year":"2001","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib145","first-page":"71","article-title":"MLL gene alterations in radiation-associated acute myeloid leukemia","volume":"27","author":"Klymenko","year":"2005","journal-title":"Exp. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib146","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2141.1987.tb01299.x","article-title":"Cytogenetic characteristics of therapy-related acute nonlymphocytic leukaemia, preleukaemia and acute myeloproliferative syndrome: correlation with clinical data for 61 consecutive cases","volume":"66","author":"Pedersen-Bjergaard","year":"1987","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib147","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib148","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2026.01.006_bib149","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib150","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.semcancer.2026.01.006_bib151","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2026.01.006_bib152","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-03-0372","article-title":"Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia","volume":"10","author":"Seedhouse","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.semcancer.2026.01.006_bib153","doi-asserted-by":"crossref","first-page":"13176","DOI":"10.1073\/pnas.95.22.13176","article-title":"Association of CYP3A4 genotype with treatment-related leukemia","volume":"95","author":"Felix","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2026.01.006_bib154","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2141.2004.05006.x","article-title":"Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML\/MDS","volume":"126","author":"Fern","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(01)00124-2","article-title":"Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1","volume":"26","author":"Haase","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2026.01.006_bib156","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V94.2.803","article-title":"Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia","volume":"94","author":"Larson","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib157","first-page":"4091","article-title":"Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia\/ myelodysplastic syndrome and de novo acute myeloid leukemia","volume":"6","author":"Naoe","year":"2000","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.semcancer.2026.01.006_bib158","article-title":"CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis","author":"Ben Khelil","year":"2025","journal-title":"Sci. Transl. Med. 17 eadu9790"},{"key":"10.1016\/j.semcancer.2026.01.006_bib159","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1038\/s41375-022-01686-y","article-title":"A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure","volume":"36","author":"Kutyna","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib160","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","article-title":"Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution","volume":"55","author":"Rodriguez-Meira","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2026.01.006_bib161","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2643-3230.BCD-19-0028","article-title":"Cytotoxic therapy-induced effects on both hematopoietic and marrow stromal cells promotes therapy-related myeloid neoplasms","volume":"1","author":"Stoddart","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.semcancer.2026.01.006_bib162","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2026.01.006_bib163","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1038\/s41375-019-0457-1","article-title":"Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome","volume":"33","author":"Bono","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib164","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood.2023020772","article-title":"VEXAS: walking on the edge of malignancy","volume":"142","author":"Malcovati","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib165","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41375-025-02814-0","article-title":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study","volume":"40","author":"Gurnari","year":"2026","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib166","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib167","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib168","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.23.01159","article-title":"Patient-specific measurable residual disease markers predict outcome in patients with myelodysplastic syndrome and related diseases after hematopoietic stem-cell transplantation","volume":"42","author":"Tobiasson","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib169","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib170","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib171","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.23.02175","article-title":"Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes","volume":"42","author":"Tentori","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib172","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood.2023022851","article-title":"Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation","volume":"143","author":"Dimitriou","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib173","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib174","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib175","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3324\/haematol.2013.098103","article-title":"p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)","volume":"99","author":"Saft","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2026.01.006_bib176","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1182\/blood-2024-201317","article-title":"Enasidenib (ENA) monotherapy in patients with IDH2 mutated myelodysplastic syndrome (MDS), the ideal phase 2 study by the GFM and Emsco Groups","volume":"144","author":"Sebert","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib177","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial","volume":"7","author":"Stein","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib178","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1016\/S2352-3026(24)00203-5","article-title":"Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial","volume":"11","author":"Della Porta","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib179","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib180","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2026.01.006_bib181","doi-asserted-by":"crossref","first-page":"19342","DOI":"10.18632\/oncotarget.25046","article-title":"Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine","volume":"9","author":"Cabez\u00f3n","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2026.01.006_bib182","doi-asserted-by":"crossref","first-page":"106948","DOI":"10.18632\/oncotarget.22157","article-title":"Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes","volume":"8","author":"Cedena","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2026.01.006_bib183","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2019.03.001","article-title":"Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis","volume":"80","author":"Du","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2026.01.006_bib184","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.semcancer.2026.01.006_bib185","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1080\/10428194.2022.2070913","article-title":"Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis","volume":"63","author":"Hu","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.semcancer.2026.01.006_bib186","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/ajh.25267","article-title":"Mutations and karyotype predict treatment response in myelodysplastic syndromes","volume":"93","author":"Idossa","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.semcancer.2026.01.006_bib187","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib188","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/bloodadvances.2022009564","article-title":"Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms","volume":"7","author":"Nannya","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2026.01.006_bib189","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/leu.2013.269","article-title":"Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms","volume":"28","author":"Traina","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2026.01.006_bib190","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:26:16Z","timestamp":1777605976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X26000131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":190,"alternative-id":["S1044579X26000131"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2026.01.006","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolutionary trajectories of myelodysplastic syndromes\/neoplasms","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}